Navigation Links
Idenix Pharmaceuticals Reports First Quarter Financial Results
Date:4/30/2009

84 and any future clinical trials involving IDX184 and expectations with respect to additional milestone payments, future royalty payments, funding of operations and future cash balances. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that historical sales of Tyzeka(R)/Sebivo(R) (telbivudine) will in any way suggest future royalty payments or royalty rates owed to the company, or that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG and GlaxoSmithKline, respectively; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's quarterly report on Form 10-K for the year ended December 31, 2008 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's ex
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, a ... groundbreaking new version of its flagship DNA design platform, which has been enhanced ... sequences into numerous genetic parts, which in turn can be recombined using specific ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... because of its properties such as low carbon footprints and compostability. These properties ... of petroleum based plastics. On the basis of applications, the market for biodegradable ...
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Israel Biomedical Sensors Market - Growth, Trends & ... The Israel Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
(Date:8/31/2015)... Mass. , Aug. 31, 2015  RXi ... company focused on discovering and developing innovative therapies ... today announced that the 30-day review period following ... (IND) for ocular indications with the U.S. Food ... IND is now active. Logo ...
Breaking Biology Technology:GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4
... MannKind Corporation (Nasdaq: MNKD ) today ... Inc. (NYSE: PFE ) to purchase Pfizer,s ... and assets related to the production of bulk insulin, ... a quantity of bulk insulin and a license to ...
... computational resources the idea of a computational laboratory ... conceptual and technical challenges. Chief among these is ... of incomplete knowledge and information, reflected in observed ... has, in recent years, grown from a collection ...
... a leading medical device/biopharmaceutical company located in Santa Ana, ... CHO-CD XP(TM) Culture System to their cell culture product ... set of chemically-defined*, serum-free, and animal component free media ... and production for recombinant CHO cell lines. It ...
Cached Biology Technology:MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 4Opportunities and challenges in uncertainty quantification for complex interacting systems 2Irvine Scientific Launches IS CHO-CD XP(TM) 2
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... University professor is helping students improve their confidence ... learning. Candice Shoemaker, professor of horticulture, has ... and self-efficacy. Self-efficacy involves student confidence in understanding ... learning and achievement. Shoemaker,s published research appeared in ...
... University of Guam ecologist Thomas Marler recently mobilized efforts ... eruption of Mount Pinatubo, Philippines. "My interest was sparked ... was so powerful it changed global climate, yet after ... ecosystem had not been studied," said Marler. ...
... of all women scientists and one-quarter of male scientists at ... them from having as many children as they had wanted, ... Methodist University (SMU). The study, "Scientists Want More ... and Anne Lincoln of SMU and appears in the current ...
Cached Biology News:Finding their way: Study shows connection between academic direction and student learning 2Finding their way: Study shows connection between academic direction and student learning 3Guam researcher studies Mount Pinatubo ecosystem recovery 2Many top US scientists wish they had more children 2Many top US scientists wish they had more children 3
... data collection and automation that is controlled from ... Excel , Pre-configured library of interfaces for ... can be added and configured by the user ... into one spreadsheet , Allows for ...
...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
One unit is equal to 10Kb (insert DNA + vector). The final cost will increase or decrease according to the final assembled genome size. The price does not include genome annotation....
Biology Products: